Abstract
Purpose: This study aimed to evaluate the impact of accumulated oral tegafur-uracil (UFUR) as maintenance chemotherapy on overall survival (OS) and disease-free survival (DFS) rates after definitive treatment for non-distant metastatic stage IV cancer of the oral cavity. Materials and methods: This retrospective, hospital center-based study analyzed data of patients diagnosed with stage IVa and IVb cancer of the oral cavity who underwent surgical resection and concurrent chemoradiotherapy (CCRT) obtained from a database between October 2008 and December 2014. Results: Forty-two patients were treated with CCRT (non-UFUR group); the remaining 51 patients received the same regimen, followed by additional oral UFUR (UFUR group). For all study patients, the 3-year DFS rates were 53.05% and 35.41% in the UFUR and non-UFUR groups, respectively (p = 0.011), while the 3-year OS rates were 74.96% and 48.47%, respectively (p = 0.001). Conclusions: Adding UFUR to CCRT significantly improved the DFS and OS rates in patients with non-distant metastatic stage IV cancer of the oral cavity.
Original language | English |
---|---|
Article number | 103156 |
Journal | American Journal of Otolaryngology - Head and Neck Medicine and Surgery |
Volume | 42 |
Issue number | 6 |
DOIs | |
Publication status | Published - Nov 1 2021 |
Keywords
- Cancer
- Metronomic
- Oral cavity
- UFUR
ASJC Scopus subject areas
- Otorhinolaryngology